Company intelligence / Profile preview

RJK Biopharma

Shanghai, Shanghai Shi, Chinakennedy24.com ↗

Ownership: Private
Development stage: Other

Overview

RJK Biopharma is a Shanghai-based biotech company developing biological products and AAV-based gene therapies targeting neurodegenerative diseases. Its lead program, RJK‑002 for ALS, has reached Phase 1 clinical trials as of November 2023. The company is recognized for its work on protein phase separation as a novel therapeutic approach to neurological disorders.

Therapeutic areas: CardiovascularOphthalmologyNeurology
Modalities: Biological productsAAV based gene therapy
Industry: Biotech

Drug pipeline

1 asset

RJK002

Partnerships

None publicly disclosed

Beyond the preview

Go deeper on RJK Biopharma.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on RJK Biopharma.

Explore the full profile